Switch theme
Sign up to access all valuation multiples
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
1993
4.8K+
LTM Revenue $921M
LTM EBITDA $23.0M
$983M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Evotec has a last 12-month revenue (LTM) of $921M and a last 12-month EBITDA of $23.0M.
In the most recent fiscal year, Evotec achieved revenue of $895M and an EBITDA of -$90.6M.
Evotec expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Evotec valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $921M | XXX | $895M | XXX | XXX | XXX |
| Gross Profit | $135M | XXX | $129M | XXX | XXX | XXX |
| Gross Margin | 15% | XXX | 14% | XXX | XXX | XXX |
| EBITDA | $23.0M | XXX | -$90.6M | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | -10% | XXX | XXX | XXX |
| EBIT | -$119M | XXX | -$88.6M | XXX | XXX | XXX |
| EBIT Margin | -13% | XXX | -10% | XXX | XXX | XXX |
| Net Profit | -$159M | XXX | -$220M | XXX | XXX | XXX |
| Net Margin | -17% | XXX | -25% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $154M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Evotec's stock price is EUR 7 (or $8).
Evotec has current market cap of EUR 1.2B (or $1.3B), and EV of EUR 875M (or $983M).
See Evotec trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $983M | $1.3B | XXX | XXX | XXX | XXX | $-0.91 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Evotec has market cap of $1.3B and EV of $983M.
Evotec's trades at 1.1x EV/Revenue multiple, and -10.9x EV/EBITDA.
Equity research analysts estimate Evotec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Evotec has a P/E ratio of -8.4x.
See valuation multiples for Evotec and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $983M | XXX | $983M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | 42.7x | XXX | -10.9x | XXX | XXX | XXX |
| EV/EBIT | -8.3x | XXX | -11.1x | XXX | XXX | XXX |
| EV/Gross Profit | 7.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -8.4x | XXX | -6.1x | XXX | XXX | XXX |
| EV/FCF | -10.2x | XXX | -7.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEvotec's last 12 month revenue growth is 9%
Evotec's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $45K for the same period.
Evotec's rule of 40 is 12% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Evotec's rule of X is 25% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Evotec and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | -10% | XXX | XXX | XXX |
| EBITDA Growth | 256% | XXX | 39% | XXX | XXX | XXX |
| Rule of 40 | 12% | XXX | -1% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 25% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $45K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Evotec acquired XXX companies to date.
Last acquisition by Evotec was XXXXXXXX, XXXXX XXXXX XXXXXX . Evotec acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Evotec founded? | Evotec was founded in 1993. |
| Where is Evotec headquartered? | Evotec is headquartered in Germany. |
| How many employees does Evotec have? | As of today, Evotec has 4.8K+ employees. |
| Who is the CEO of Evotec? | Evotec's CEO is Mr. Christian Wojczewski, PhD. |
| Is Evotec publicy listed? | Yes, Evotec is a public company listed on ETR. |
| What is the stock symbol of Evotec? | Evotec trades under EVT ticker. |
| When did Evotec go public? | Evotec went public in 1999. |
| Who are competitors of Evotec? | Similar companies to Evotec include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Evotec? | Evotec's current market cap is $1.3B |
| What is the current revenue of Evotec? | Evotec's last 12 months revenue is $921M. |
| What is the current revenue growth of Evotec? | Evotec revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Evotec? | Current revenue multiple of Evotec is 1.1x. |
| Is Evotec profitable? | Yes, Evotec is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Evotec? | Evotec's last 12 months EBITDA is $23.0M. |
| What is Evotec's EBITDA margin? | Evotec's last 12 months EBITDA margin is 3%. |
| What is the current EV/EBITDA multiple of Evotec? | Current EBITDA multiple of Evotec is 42.7x. |
| What is the current FCF of Evotec? | Evotec's last 12 months FCF is -$96.4M. |
| What is Evotec's FCF margin? | Evotec's last 12 months FCF margin is -10%. |
| What is the current EV/FCF multiple of Evotec? | Current FCF multiple of Evotec is -10.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
